SEC Form 10-Q filed by Apogee Therapeutics Inc.
$APGE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2026 | $140.00 | Buy | Rothschild & Co Redburn |
| 3/18/2026 | $83.00 | Hold | Truist |
| 1/22/2026 | $83.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 1/7/2026 | Peer Perform | Wolfe Research | |
| 12/17/2025 | $95.00 | Overweight | Stephens |
| 12/10/2025 | $103.00 | Buy | Deutsche Bank |
| 11/3/2025 | $109.00 | Buy | Craig Hallum |
| 10/21/2025 | $105.00 | Outperform | Mizuho |
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Fireside Time: 11:40 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Time: 9:20 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentia
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time SAN FRANCISCO and BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class pr
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart was well tolerated with a safety profile consistent with other agents in class Strategic financing collaboration with Blackstone Life Sciences announced today expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE Results support pipeline-in-a-product potential for zumilokibart with asthma and eosinophilic esophagitis (EoE) trial plans shared today Management to host conference call today at 8:00 a.m. ET SAN FRANCISCO and BOSTON, May
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
Rothschild & Co Redburn initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $140.00
Truist initiated coverage of Apogee Therapeutics with a rating of Hold and set a new price target of $83.00
RBC Capital Mkts downgraded Apogee Therapeutics from Outperform to Sector Perform and set a new price target of $83.00
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart was well tolerated with a safety profile consistent with other agents in class Strategic financing collaboration with Blackstone Life Sciences announced today expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE Results support pipeline-in-a-product potential for zumilokibart with asthma and eosinophilic esophagitis (EoE) trial plans shared today Management to host conference call today at 8:00 a.m. ET SAN FRANCISCO and BOSTON, May
SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics' live webcast of the Phase 2 APEX Part B results will begin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed via this l
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients maintained vIGA 0/1Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart Well tolerated across both dosing regimens, with safety profile generally in line with other agents in class APEX Part B 16-week induction expected to readout 2Q 2026, supporting expected initiation of Phase 3 zumilokibart trials in moderate-to-severe atopic dermatitis starting in 2H 2026 Dat
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)